Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 11/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 9/20 | 0.45 |
| ▸ | CTSB | P07858 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297940 | 0.92 | MEN1 (0.46) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL8727726 | 0.90 | MEN1 (0.49) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL8906441 | 0.85 | CTSS (0.47) | MEN1KMT2ACTSSCTSLCTSB | |
| SCHEMBL560561 | 0.79 | PTPN2 (0.55) | MEN1KMT2APTPN2PTPN1PTPRB | |
| SCHEMBL2297713 | 0.78 | PTPN2 (0.54) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL17896152 | 0.78 | CTSS (0.40) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL12385413 | 0.77 | CTSS (0.49) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL8914440 | 0.77 | CTSS (0.49) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL15056984 | 0.77 | KMT2A (0.56) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL1150695 | 0.76 | CTSS (0.58) | MEN1KMT2ACTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190497-A1 | Process for production of 2,5 dioxopyrrolidine 3 carboxylate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190497-A1 | Process for production of 2,5 dioxopyrrolidine 3 carboxylate | REN, PKD1, KCNT1 | MEN1 1567/4885KMT2A 1094/4885CTSS 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.